Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that reduces gastric acid production.
## Primary Indications
* Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD).
* Maintenance of healing of erosive esophagitis.
* Treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome.
## Adult Dosing
* **Healing of Erosive Esophagitis:** 40 mg orally or intravenously once daily for up to 8 weeks.
* **Maintenance of Healing of Erosive Esophagitis:** 40 mg orally once daily. Some patients may be managed on 20 mg orally once daily.
* **Pathological Hypersecretory Conditions (e.g., Zollinger-Ellison Syndrome):** Initial dose is typically 40 mg orally or intravenously twice daily. Doses may be adjusted based on gastric acid output. Maximum dose is 240 mg daily.
## Pediatric Dosing
* **GERD (patients 5 to 16 years):** 20 mg orally once daily for up to 8 weeks for healing of erosive esophagitis.
* Dosing for pathological hypersecretory conditions in pediatric patients is not established and should be guided by specialist consultation.
## Dose Adjustments
* No specific dose adjustments are recommended for patients with hepatic impairment; however, caution is advised. A maximum daily dose of 40 mg should not be exceeded in patients with moderate to severe hepatic impairment.
* No dose adjustment is generally needed for renal impairment.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
## Adverse Effects
* **Common:** Headache, diarrhea, nausea, abdominal pain, vomiting, flatulence, dizziness.
* **Serious:** *Clostridioides difficile*-associated diarrhea, bone fracture (hip, wrist, spine), hypomagnesemia, vitamin B12 deficiency, fundic gland polyps.
## Key Drug Interactions
* **Drugs requiring gastric acid for absorption:** Absorption may be decreased for drugs like ketoconazole, itraconazole, posaconazole, iron salts, and vitamin B12.
* **Methotrexate:** PPIs may increase methotrexate levels.
* **Certain HIV medications:** Delavirdine, nelfinavir.
* **CYP2C19 substrates:** Pantoprazole is a moderate inhibitor of CYP2C19.
## Monitoring
* Electrolytes (especially magnesium) with prolonged use.
* Bone mineral density with long-term therapy.
* Monitor for signs and symptoms of *C. difficile* infection.
## Clinical Pearls
* Administer oral pantoprazole 30 minutes to 1 hour before a meal.
* For intravenous administration, reconstitute and infuse over 15 minutes or longer.
* Long-term use of PPIs is associated with increased risk of fractures, *C. difficile* infection, hypomagnesemia, and vitamin B12 deficiency. Reassess the need for continued therapy periodically.
***
*Disclaimer: This information is intended for clinical use and does not replace professional judgment. Always verify current prescribing information with the official product monograph and relevant clinical guidelines.*
